Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ASKA Pharmaceutical has entered into a licensing agreement with HRA Pharma, under which ASKA will take care of the development and marketing of ulipristal acetate in Japan for emergency contraception.
Subscribe to our email newsletter
Ulipristal acetate is an orally active selective progesterone receptor modulator that reversibly blocks the progesterone receptors in targeted tissues.
It is marketed as ellaOne in Europe as well as ella in the US.
In clinical trials ellaOne has demonstrated efficacy with safety and tolerability profile.
The drug is currently available to women in the UK, France, Germany, and 23 other major European countries.
HRA Pharma CEO Erin Gainer said their mission is to make their products widely available on a worldwide basis and they are delighted that women in Japan will now have access to ellaOne.
ASKA CEO Yamaguchi said they are expecting ellaOne to follow on NorLevo (levonorgestrel) another product related to emergency contraception to which ASKA also has the marketing rights in Japan.